Notes

May14issuer8Kexhibit99.1 explicitlysetsAmeluzsBCCSep28 2026PDUFA. Aug13exhibitretainslateSeptemberwindow,launchQ1 2027ifapproved. Q2revenue12m+32.9%,GM80%,adjustedEBITDA-.2m;issueracknowledgesorderpullforwardbeforeXL ITCrestrictionJuly7 andassertsmajorityinstalledbaseunaffected. May6orderversusJuly7effective isdifferentmilestones,notcontradiction. Unitgrowthandmarginimprovebutnotcleanorganicrepeatablequarter. Dateverificationdoesnotresolvegap,financingorlabelrisk;sharegrowthDec31-Aug11=27.5064%calculatedfrom10Q. https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm ; https://www.sec.gov/Archives/edgar/data/1858685/000149315226037610/ex99-1.htm

RetrievedSep6: overview expectsAgave4.3October2026 whileAlpenglowdetail datedJune stillQ3; exact activationday not verified. ReducedrentSepupdated reportsfirststepSep3epoch1028:6960->6333lamports/byte;secondmainnetmidSepwindow;final3stepsNovAgave4.4. Refundable storagebond,not transactionfee. Largertransactions pendingactivation4096vs1232bytes;September9 media claim not accepted without original date/config. Roadmappages sameorigin, not independentcorroboration; no trade. https://solana.com/upgrades ; https://solana.com/upgrades/alpenglow ; https://solana.com/el/upgrades/reduced-rent ; https://solana.com/upgrades/larger-transaction-sizes

Issuer10Q filedAug13 2026, periodJun30: cash4.7m vs6.4mDec31;6month operatingoutflow1.7m;substantial doubt goingconcern for12months;Aug11 outstanding14,852,359 vsDec31 11,648,323. May6 ITC limitedexclusion/cease-desist affectsRhodoLED XL andAmeluz usewithXL;not a claim allAmeluz barred. 0.5mestimatedremediation and following12monthdisbursement forecast. Report is closest financial source; exact FDAdate not located in retrieved10Q and must be independently primary-verified. Do not equate annualizing1.7m cashburn with a reliable runway. https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm

May11 2026 issuer exhibit, quarter endedMar31: sales338m down13%;organic-6%=volume/mix-11points+pricing5points;GM20.8%down90bp;adjustedEBITDA26mvs34m;operatingcash38m,FCF35m;debt549m/netdebt505m/netsecuredleverage4.3x. Debt reduction partly follows divestiture, not purely recurring operating cash. One issuer origin, not independent SEC corroboration. September14beforeopen date confirmed separately. https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/hain-ex99_1.htm

Issuer June15 2026, quarter endedApr30: CAD179.3m revenue,13.9m adjustedEBITDA,1.5m FCF versus4.9mYoY/2.9m sequential; grossmargin27%,German distributionmargin27%versus12%previousquarter; trailing4Q FCF13.4m. Company says working-capital investment caused weakerFCF. NonIFRS measures, management-promotional source; cash conversion1.5/13.9=10.79% diagnostic, not audited EBITDA-to-cash reconciliation. https://hightideinc.com/high-tide-reports-second-quarter-2026-financial-results-featuring-record-revenue-of-179-3mm-and-adjusted-ebitda-of-13-9mm/

Issuer Aug4 2026, quarter endedJul31: revenue/grossprofit/adjustedEBITDA expected growth at least30%/27%/43%; Remexian shipped >10tonnes, +33%sequential,+60%YoY. Canada same-store sales positive June/July. Full releaseSep14afterclose. Promotional estimates, unaudited, not independent shipment validation; management claim versus Aug3FactSet not our verified consensus. Cannot treat these as new September14 surprises. https://hightideinc.com/high-tide-announces-preliminary-q3-2026-guidance/

Retrieved Sep6 02UTC: issuer press-release index dates LISRAYA FDA approval Aug27 2026; events page lists approval call Aug28 08ET. Prior August6 report/annual letter described Q3 expected action/launch. Issuer is closest corporate source but promotional; dates refer to separate periods, not contradiction. Exclude already-completed approval from prospective run-up screen; no assumed September PDUFA. https://investor.roivant.com/news-events/press-releases ; https://investor.roivant.com/news-events/events/

At 00:14:38 UTC on September 6, 17 automated systems, called catalyst monitors, were watching the market, and none were scheduled to run before 02 UTC. Four new research reviews, numbered 31 to 34, were added, but no orders to buy or sell were made. The fund had 49.14 in cash, no proposals, and no positions were reset. A complete 63-part archive of data and code was kept, and exact metrics were recorded, which included three lessons, numbered 95 to 97. The decision made was that there was not a proven, reliable advantage, called an executable edge, and not a prediction that every watched stock would fall. runway:list_monitors?fund=catalyst ; runway:query_trades?fund=catalyst ; analyses210,211,220

A news scan found the headline 'Python calculations Sep6 2026'. This is a data line showing the results of automated trading calculations made on September 6, 2026. The rules used for these calculations were frozen and all the inputs are stored in an archive. The exact metrics from these calculations are as follows: the sample size was 3, the win rate percentage was 0, the mean return percentage was -16.380601133687552, the average loss percentage was 16.380601133687552, there were 2 operator exits, 1 stop exit, and 0 target exits. Additionally, the rare loss percentage was 45.860061919504645, the rare gap beyond stop percentage was -41.70933333333333, the repeat rare loss on fund was 22.535634427244585, and the equity risk budget was 8.5099. runway:query_trades?fund=catalyst